atrial natriuretic peptide
Atrial natriuretic peptide (ANP) or atrial natriuretic factor (ANF) is a natriuretic peptide hormone secreted from the cardiac atria that in humans is encoded by the NPPA gene. Natriuretic peptides are a family of hormone/paracrine factors that are structurally related. The main function of ANP is causing a reduction in expanded extracellular fluid (ECF) volume by increasing renal sodium excretion. ANP is synthesized and secreted by cardiac muscle cells in the walls of the atria in the heart. These cells contain volume receptors which respond to increased stretching of the atrial wall due to increased atrial blood volume. — Wikipedia
Clinical trial activity
6 trials · 8 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 1999 (NCT00030121)
Timeline
Indications
Approved for
Mechanism of action
Chemistry & pharmacology
SMILES
CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O- Mol. weight
- 3080.5 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAtrial natriuretic peptide ↗
- ChEMBLCHEMBL2104386 ↗
Also known as
- alpha-atrial natriuretic peptide, human
- alpha-hanp
- alpha-human atrial natriuretic peptide
- atrial natriuretic peptide
- atrial natriuretic peptide precusor a, human
- atrial natriuretic polypeptide
- atrial natriuretic polypeptide
- atriopeptin
- carperitide
- carperitide
- carperitide
- carperitide
- carperitide
- carperitide
- carperitide
- carperitide (recombinant)
- human atrial natriuretic peptide
- natriuretic peptide precursor a, human
- nppa protein, human
- sun-4936
- sun-4936
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02665377 | Phase 3 | Sep 1, 2016 | University of Gothenburg |
| NCT01260103 | Phase 3 | Dec 1, 2011 | Burzynski Research Institute |
| NCT00613964 | Phase 4 | May 1, 2009 | Nara Medical University |
| NCT00259038 | Phase 2 | Jan 1, 2004 | Astellas, Daiichi Sankyo |
| NCT00212056 | N/A | Oct 1, 2001 | Japan Cardiovascular Research Foundation, National Cerebral and Cardiovascular Center |
| NCT00030121 | Phase 2 | Dec 1, 1999 | Suntory Pharmaceutical |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 1 | 0 | 1 | 2004 |
| Burzynski Research Institute | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Daiichi Sankyo | For profit | 1 | 1 | 1 | 2004 |
| Japan Cardiovascular Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2001 |
| Nara Medical University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| National Cerebral and Cardiovascular Center | Government | 1 | 1 | 1 | 2001 |
| Suntory Pharmaceutical | For profit | 1 | 1 | 1 | 1999 |
| University of Gothenburg | Academic/Hospital | 1 | 1 | 1 | 2016 |